Prognomix Inc.

Prognomix Inc. is a privately held Personalized Medicine company focused on discovery and clinical application of genomic signatures predictive of susceptibility to diseases, their complications and individual therapeutic responsiveness. Since its inception, the company has made significant progress in the identification of the genomic features associated with complications of type 2 diabetes. Based on these findings, which have been the object of patent filings, the company has developed a first generation prototype of a molecular diagnostic kit. The company will soon submit this prototype to validation using independent sample sets and refine it by inclusion of clinical biomarkers and other genomic and epigenomic features. - canadian online casinos